KRAS-mutant lung adenocarcinomas often carried loss-of-function mutations in KEAP1 [66], and co-mutations involving the PI3K-AKT-mTOR and NRF2 pathways, such as NFE2L2 amplification combined with loss of STK11, have also been observed [67]. Here, NFE2L2 is linked to lung adenocarcinoma.